Abstract: Provided herein are compounds useful for selectively labeling an apoptotic cell, and methods and assays using such compounds for the detection of an apoptotic cell in vivo or in a biological sample obtained from a subject.

Abstract: The disclosure provides cross-linked materials that include multivalent cross-linking agents that bind an exogenous target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with the exogenous target molecule for binding with the cross-linking agents and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between cross-linking agents and affinity ligands on different conjugates. The conjugates also include a drug.

Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.

Abstract: This invention discloses a surgical prep solution formulation, either film forming or non-film forming, that changes color upon a change in pH to indicate that the solvent has sufficiently evaporated. The major components of this surgical prep solution include: antimicrobial agents, solvents, pH adjusters, color changing pH indicators, and optionally: film forming polymers, dyes and viscosity regulators. The pH of the solution may rise or fall depending on the pH of the original solution as compared with the normal pH range of the acid mantle of the human skin or the normal pH range of a sterilizing solution. As the pH changes, the pH indicator may cause the surgical prep solution to change color. Concurrently, as the fluids evaporate, the pH indicators interact with atmospheric CO2, causing the solution to change color based on the pH of the solution. The solution may also be used as coating for medical devices.

Abstract: A non-aqueous single pot synthesis of [18F]SFB is set forth. The [18F]SFB produced with this method is then used, for example, to label a peptide or an engineered antibody fragment (diabody) targeting human epidermal growth factor receptor 2 (HER2) as representative examples of labeled compounds for use as an injectable composition to locate abnormal tissue, specifically tumors within an animal or human using a PET scan.

Abstract: A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.

Abstract: Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented: wherein Q is a portion of a polymethine bridge: Also included are bioconjugates of the compounds of Formula I, methods of labeling biomolecules with the compounds, and methods of imaging.

Abstract: The application relates to a nanovesicle comprising a bilayer of at least 15 mol % porphyrin-phospholipid conjugate, wherein the conjugate comprises a porphyrin, porphyrin derivative or porphyrin analog covalently attached to the phospholipid side chain. The nanovesicle can be used for photothermal therapy, photoacoustic imaging, and fluorescence imaging. The application also discloses a method of preparing the said nanovesicle.

Abstract: Disclosed are lipidomimetic compounds of formula I (I) wherein: G represents a group satisfying formula II: HO—CH2—{CH(OH)—CH2-0}m-CH2—{C(=0)-0-CH2})q— formula II each n independently is an integer from 1-30; m is an integer from 1-10; q is 0 or 1. These compounds can be added to the lipid bilayer of thermosensitive liposomes, for the purpose of aiding in the prevention of leakage of the liposomes' contents at 37° C., and retarding clearance from circulation.

Abstract: This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer 99mTc(CO)3(NTA) (technetium-99m tricarbonyl-nitrilotriacetic acid). The disclosure encompasses methods of imaging the kidneys and measuring effective renal plasma flow (ERPF) in an animal or human subject using renal scintigraphy, comprising administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99mTc-(CO)3(NTA). Another aspect of the disclosure are methods of measuring effective renal plasma flow in an animal or human subject, comprising administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99mTc-(CO)3(NTA), isolating a series of plasma samples from the animal or human subject after administering the renal tracer and quantitatively detecting the amount of the renal tracer in the biological samples.

Abstract: The present invention relates to linker molecules that readily conjugate cellular recognition ligand at one end and drug payload at the other, and are useful in treating or preventing cancer, an autoimmune disease, an inflammatory condition, a central nervous system disorder or an infection.

Abstract: The present invention relates to a method for the generation of 223Ra of pharmaceutically tolerable purity comprising: i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra in a first aqueous solution comprising a first mineral acid; ii) loading said generator mixture onto a DGA separation medium (e.g. resin); iii) eluting said 223Ra from said DGA separation medium using a second mineral acid in a second aqueous solution to give an eluted 223Ra solution; and iv) stripping the DGA separation medium of said 227Ac and 227Th by flowing a third mineral acid in a third aqueous solution through the DGA separation medium in a reversed direction; The invention further relates to high purity radium-223 formed or formable by such a method as well as pharmaceutical compositions comprising such radium-223 of pharmaceutical purity.

Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.

Abstract: The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.

Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.

Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Abstract: In certain embodiments novel nanoparticles (nanowontons) are provided that are suitable for multimodal imaging and/or therapy. In one embodiment, the nanoparticles include a first biocompatible (e.g., gold) layer, an inner core layer (e.g., a non-biocompatible material), and a biocompatible (e.g., gold) layer. The first gold layer includes a concave surface that forms a first outer surface of the layered nanoparticle. The second gold layer includes a convex surface that forms a second outer surface of the layered nanoparticle. The first and second gold layers encapsulate the inner core material layer. Methods of fabricating such nanoparticles are also provided.

Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Abstract: The invention relates to a strontium-82/rubidium-82 generator, comprising a column filled with a cationic exchanger loaded with strontium-82, and having an inlet and an outlet, and a liquid medium, wherein parts of the column, inlet and outlet coming into contact with the liquid medium are iron-free, preferably metal-free, to a method for producing rubidium-82, and to the obtained diagnostic agent.

Abstract: A medical delivery system that enables the delivery of therapeutic agents to malignant tissue utilizing delivery agents and heating of the delivery agents thereby causing the release of the therapeutic agents within the tumor is disclosed. The therapeutic agents may be chemotherapy agents, radiation therapy agents, and other appropriate materials. The magnetic nanoparticles encapsulated by the therapeutic agents in a biocompatible coating may be delivered to tumor sites utilizing attenuated strains of bacteria that seek and reside at tumor sites. An alternating magnetic field device with a prescribed frequency range may be used to induce heating of the magnetic nanoparticles in the patient thereby melting the coating and releasing the therapeutic agents within the tumor.